LEADER 06106nam 22006375 450 001 9910996488703321 005 20250415145348.0 010 $a3-031-83005-9 024 7 $a10.1007/978-3-031-83005-1 035 $a(CKB)38428960300041 035 $a(DE-He213)978-3-031-83005-1 035 $a(MiAaPQ)EBC32010863 035 $a(Au-PeEL)EBL32010863 035 $a(OCoLC)1524424306 035 $a(EXLCZ)9938428960300041 100 $a20250415d2025 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntibody-Drug Conjugates $eThe 21st Century Magic Bullets for Cancer /$fedited by Jennica L. Zaro, Jeffrey Wang 205 $a2nd ed. 2025. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2025. 215 $a1 online resource (IX, 299 p. 53 illus., 23 illus. in color.) 225 1 $aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-738X ;$v17 311 08$a3-031-83004-0 327 $a1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions. 330 $aThe field of antibody-drug conjugates (ADCs) has undergone remarkable advancements in recent years, marked by significant progress in both drug approvals and ongoing clinical development. Since the approval of the first ADC in 2010 (gemtuzumab ozogamicin, Mylotarg®), the landscape has expanded dramatically. Today, there are 11 FDA-approved ADCs, targeting a variety of cancers across multiple indications. The approved ADCs include a range of payloads, linkers, and antibodies, each optimized for a variety of specific therapeutic targets. The increasing diversity of ADCs reflects the growing potential of these innovative treatments to address a wide array of malignancies, from hematologic cancers to solid tumors. This book aims to provide a comprehensive overview of the current state of the ADC field including the latest developments, challenges, and emerging trends, comprising expertise from a broad range of disciplines from basic research, industry, clinical practice and regulatory affairs. We explore not only the scientific and technical aspects of ADC design?such as payloads, linkers, and antibody selection?but also the developmental hurdles and regulatory complexities that influence the success of ADCs in clinical practice. Real-world examples of ADCs that have made it from the lab to the clinic offer invaluable insights into the trials and triumphs that shape this dynamic field. It is our hope that this book will serve as both a valuable resource for experts in the field and an accessible introduction for those new to the exciting world of ADCs. Dr. Jennica Zaro earned her Ph.D. in Pharmaceutical Sciences from the University of Southern California (USC). Her research focuses on the targeted delivery of peptide and protein drugs, as well as the development of recombinant bifunctional fusion proteins as therapeutics. Dr. Zaro is currently an Associate Professor at the USC School of Pharmacy and Pharmaceutical Sciences. She has held several academic administrative roles, including Core Director of the Translational Research Laboratory and Assistant Dean of Assessment for Graduate Education at USC, and Assistant Dean of Assessment at West Coast University. In addition to her academic roles, she has significant experience in the pharmaceutical industry, where she contributed to the development of formulations for aerosol products and designed and validated analytical methods for protein drugs. Dr. Jeffrey Wang received a BS degree from the School of Pharmacy, Shanghai Medical University and a PhD degree in pharmaceutical sciences from the University of Southern California. Dr. Wang?s research focuses on the application of principles of pharmacokinetics and drug metabolism in drug discovery and delivery, particularly in anti-cancer drug discovery and peptide drug delivery. He has published over 80 peer-reviewed articles and book chapters, and is the co-inventor of several US and international patents. Dr. Wang is currently a Professor of Biotechnology and Pharmaceutical Sciences and Associate Dean for Research and Global Advancement at the College of Pharmacy, Western University of Health Sciences. 410 0$aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-738X ;$v17 606 $aPharmacology 606 $aPharmaceutical chemistry 606 $aCancer$xTreatment 606 $aDrug delivery systems 606 $aPharmacology 606 $aPharmaceutics 606 $aCancer Therapy 606 $aDrug Delivery 615 0$aPharmacology. 615 0$aPharmaceutical chemistry. 615 0$aCancer$xTreatment. 615 0$aDrug delivery systems. 615 14$aPharmacology. 615 24$aPharmaceutics. 615 24$aCancer Therapy. 615 24$aDrug Delivery. 676 $a615 702 $aZaro$b Jennica L$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aWang$b Jeffrey$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910996488703321 996 $aAntibody-drug conjugates$92231062 997 $aUNINA LEADER 02955nam 2200601 a 450 001 9910961269503321 005 20260218181344.0 010 $a1-282-95113-0 010 $a9786612951138 010 $a90-474-4395-0 024 7 $a10.1163/ej.9789004179653.i-236 035 $a(CKB)2670000000066588 035 $a(EBL)634980 035 $a(OCoLC)695990039 035 $a(SSID)ssj0000439193 035 $a(PQKBManifestationID)11332224 035 $a(PQKBTitleCode)TC0000439193 035 $a(PQKBWorkID)10464082 035 $a(PQKB)10754615 035 $a(MiAaPQ)EBC634980 035 $z(OCoLC)460056815 035 $a(nllekb)BRILL9789047443957 035 $a(Au-PeEL)EBL634980 035 $a(CaPaEBR)ebr10439149 035 $a(CaONFJC)MIL295113 035 $a(PPN)17074177X 035 $a(EXLCZ)992670000000066588 100 $a20090817d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aLutheran humanists and Greek antiquity $eMelanchthonian scholarship between universal history and pedagogy /$fby Asaph Ben-Tov 205 $a1st ed. 210 $aLeiden [Netherlands] ;$aBoston $cBrill$d2009 215 $a1 online resource (248 p.) 225 1 $aBrill's studies in intellectual history,$x0920-8607 ;$vv. 183 300 $aBased on the author's thesis--Hebrew University in Jerusalem. 311 08$a90-04-17965-8 320 $aIncludes bibliographical references and index. 327 $aGreek antiquity in Lutheran universal history -- Lutheran humanists and Byzantium: the scope of Greek antiquity -- Lutheran humanists on Greek: the history of Greek and Greek in history -- Some Lutheran readings of Greek texts -- Graecia transvolavit Alpes. 330 $aThe textual monuments of Greco-Roman antiquity, as is well known, were a staple of Europe?s educated classes since the Renaissance. That the Reformation ushered in a new understanding of human fate and history is equally a commonplace of modern scholarship. The present study probes attitudes towards Greek antiquity by of a group of Lutheran humanists. Concentrating on Philipp Melanchthon, several of his colleagues and students, and a broader Melanchthonian milieu, a Lutheran understanding of Pagan and Christian Greek antiquity is traced in its sixteenth century context, positing it within the framework of Protestant universal history, pedagogical concerns, and the newly made acquaintance with Byzantine texts and post-Byzantine Greeks ? demonstrating the need to historicize Antiquity itself in Renaissance studies and beyond. 410 0$aBrill's studies in intellectual history ;$vv. 183. 676 $a938.0072/02 700 $aBen-Tov$b Asaph$01893855 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910961269503321 996 $aLutheran humanists and Greek antiquity$94543540 997 $aUNINA